<p> New Delhi: Drug firm Granules India on Tuesday said it has received approval from the US health regulator to market a medication used to prevent or treat gout attacks.</p>.<p> Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of the company, has received approval from the US Food & Drug Administration (USFDA) for Colchicine Capsules (0.6 mg), it said in a regulatory filing.</p>.<p> The company's product is therapeutically equivalent to Hikma International Pharmaceuticals LLC's Mitigare Capsules (0.6 mg), it added.</p>.Covishield developer AstraZeneca admits its vaccine can cause side effects in 'very rare cases'.<p> Colchicine Capsules are indicated for prophylaxis of gout flares in adults.</p>.<p> According to industry sources, the current annual market for Colchicine Capsules in the US is expected to be around $55 million.</p>
<p> New Delhi: Drug firm Granules India on Tuesday said it has received approval from the US health regulator to market a medication used to prevent or treat gout attacks.</p>.<p> Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of the company, has received approval from the US Food & Drug Administration (USFDA) for Colchicine Capsules (0.6 mg), it said in a regulatory filing.</p>.<p> The company's product is therapeutically equivalent to Hikma International Pharmaceuticals LLC's Mitigare Capsules (0.6 mg), it added.</p>.Covishield developer AstraZeneca admits its vaccine can cause side effects in 'very rare cases'.<p> Colchicine Capsules are indicated for prophylaxis of gout flares in adults.</p>.<p> According to industry sources, the current annual market for Colchicine Capsules in the US is expected to be around $55 million.</p>